Hepatocyte growth factor as inducer of gefitinib resistance in non-small cell lung cancer harboring EGFR activating mutations

被引：0
|
作者：
Yano, S.
Wang, W.
Li, Q.
Yamada, T.
Matsumoto, K.
Mitsudomi, T.
Yatabe, Y.
Hanibuchi, M.
Nishioka, Y.
Sone, S.
机构：
[1] Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa 920, Japan
[2] Aichi Canc Ctr, Nagoya, Aichi 464, Japan
[3] Univ Tokushima, Grad Sch, Tokushima 770, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19034
引用
收藏
页数：1
相关论文
共 50 条
  • [41] EGFR GENE MUTATIONS IN ADVANCED NON-SMALL CELL LUNG CANCER AND ITS INFLUENCE ON EFFECT OF GEFITINIB
    Zhong, W.
    Xia, Y.
    Wang, M-Z
    Chen, M-J
    Zhang, L.
    Zhao, J.
    Li, L-Y
    RESPIROLOGY, 2011, 16 : 146 - 146
  • [42] First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations
    Kuwako, Tomohito
    Imai, Hisao
    Masuda, Tomomi
    Miura, Yosuke
    Seki, Kaori
    Yoshino, Reiko
    Kaira, Kyoichi
    Utsugi, Mitsuyoshi
    Shimizu, Kimihiro
    Sunaga, Noriaki
    Tomizawa, Yoshio
    Ishihara, Shinichi
    Ishizuka, Takao
    Mogi, Akira
    Hisada, Takeshi
    Minato, Koichi
    Takise, Atsushi
    Saito, Ryusei
    Yamada, Masanobu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 761 - 769
  • [43] The pulmonary source of hepatocyte growth factor in non-small cell lung cancer
    Chow, Kuan-Chih
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2007, 36 (01) : 131 - 132
  • [44] The clinical significance of hepatocyte growth factor for non-small cell lung cancer
    Siegfried, JM
    Weissfeld, LA
    Luketich, JD
    Weyant, RJ
    Gubish, CT
    Landreneau, RJ
    ANNALS OF THORACIC SURGERY, 1998, 66 (06): : 1915 - 1918
  • [45] Transcriptional Profiling of Non-Small Cell Lung Cancer Cells with Activating EGFR Somatic Mutations
    Choi, Kuicheon
    Creighton, Chad J.
    Stivers, David
    Fujimoto, Nobukazu
    Kurie, Jonathan M.
    PLOS ONE, 2007, 2 (11):
  • [46] Impact of body surface area on efficacy of gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutation.
    Ichihara, Eiki
    Hotta, Katsuyuki
    Hisamoto, Akiko
    Takigawa, Nagio
    Tabata, Masahiro
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations A Review
    Passaro, Antonio
    Mok, Tony S. K.
    Attili, Ilaria
    Wu, Yi-Long
    Tsuboi, Masahiro
    de Marinis, Filippo
    Peters, Solange
    JAMA ONCOLOGY, 2023, 9 (08) : 1124 - 1131
  • [48] Combining Onartuzumab with Erlotinib Inhibits Growth of Non-Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
    Sano, Yuji
    Hashimoto, Eri
    Nakatani, Noriaki
    Abe, Masaichi
    Satoh, Yasuko
    Sakata, Kiyoaki
    Fujii, Toshihiko
    Fujimoto-Ouchi, Kaori
    Sugimoto, Masamichi
    Nagahashi, Shigehisa
    Aoki, Masahiro
    Motegi, Hiroshi
    Sasaki, Eiichi
    Yatabe, Yasushi
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (02) : 533 - 541
  • [49] Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis
    Eduardo Castañón
    Christian Rolfo
    David Viñal
    Inés López
    Juan P Fusco
    Marta Santisteban
    Patricia Martin
    Leire Zubiri
    José I Echeveste
    Ignacio Gil-Bazo
    Journal of Translational Medicine, 13
  • [50] Analysis of non-small cell lung cancer with miliary lung metastasis in patients harboring epidermal growth factor receptor mutations
    Ming-Hung Chang
    Kuo-Hwa Chiang
    Jiunn-Min Shieh
    Kuo-Chen Cheng
    Chung-Han Ho
    Scientific Reports, 12
12345